{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:54:02Z","timestamp":1794376442194,"version":"4.9.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy and safety of vibegron add\u2010on therapy for persistent overactive bladder (OAB) symptoms after\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker monotherapy for benign prostatic hyperplasia (BPH).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eligible patients were aged \u2265\u200950\u2009years and diagnosed with BPH. All patients had received an\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker for \u2265\u20098\u2009weeks, yet had persistent OAB symptoms. Patients were randomized 1:1 to receive add\u2010on vibegron (50\u2009mg) or to continue\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker monotherapy. The primary efficacy endpoint was the between\u2010group difference from baseline (week 0) to week 12 in total overactive bladder symptom score (OABSS). Secondary endpoints included bladder diary parameters, OABSS subscores; International Prostate Symptom Score total, storage\/voiding, quality\u2010of\u2010life score; and patient satisfaction assessed by the Patient Global Impression. Safety was assessed by recording treatment\u2010emergent adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 158 patients were randomized into two groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979 each). The least\u2010squares mean change in the primary endpoint (OABSS total score) was \u22121.9 (95% confidence interval [CI]: \u22122.4 to \u22121.5) with\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker monotherapy and \u22123.3 (95% CI: \u22123.8 to \u22122.9) with vibegron add\u2010on therapy; the between\u2010group difference was \u22121.4 (95% CI: \u22122.0 to \u22120.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), indicating a significant improvement with add\u2010on therapy. Across the secondary endpoints, favorable outcomes were observed. Higher satisfaction was reported in the vibegron add\u2010on therapy group than in the\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker monotherapy group. Vibegron was well tolerated, and no serious drug\u2010related treatment\u2010emergent adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Vibegron add\u2010on therapy to an\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      \u2010blocker may be effective and safe for treating BPH with persistent OAB symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/luts.70053","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:55:52Z","timestamp":1773471352000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Vibegron Add\u2010On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With \u03b1\n                    <sub>1<\/sub>\n                    \u2010Blocker Treatment: A Multi\u2010Center Prospective Randomized Controlled Study (\n                    <scp>VATON<\/scp>\n                    Study)"],"prefix":"10.1111","volume":"18","author":[{"given":"Masaki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Urology Sakurajyuji Hospital  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Nishino","sequence":"additional","affiliation":[{"name":"Nishino Clinic  Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagae","sequence":"additional","affiliation":[{"name":"Nagae Prostate Care Clinic  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Kato","sequence":"additional","affiliation":[{"name":"Kato Urological Clinic  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaaki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology Nakamura Hospital  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morifumi","family":"Hojo","sequence":"additional","affiliation":[{"name":"Department of Urology Koga Hospital 21  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Urology Oita Urology Hospital  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Kageyama Clinic  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Takahashi Urological Clinic  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideya","family":"Kuroda","sequence":"additional","affiliation":[{"name":"KURODA UROLOGY CLINIC  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology Tagawa Municipal Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kasagi","sequence":"additional","affiliation":[{"name":"Kasagi Urology Clinic  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Masunaga","sequence":"additional","affiliation":[{"name":"Itabashi Tokumaru Clinic  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nabeshima","sequence":"additional","affiliation":[{"name":"Department of Urology Fukuoka Tokushukai Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nomiya","sequence":"additional","affiliation":[{"name":"Department of Urology National Center for Geriatrics and Gerontology  Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Iwashita","sequence":"additional","affiliation":[{"name":"Shiizako Urological Clinic  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Maehara Urology Clinic  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Otani","sequence":"additional","affiliation":[{"name":"Otani Clinic  Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kawahara","sequence":"additional","affiliation":[{"name":"KAWAHARA Nephro\u2010Urology Clinic  Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8950-6129","authenticated-orcid":false,"given":"Makoto","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyorin Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kubono","sequence":"additional","affiliation":[{"name":"Medical Department Kissei Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Urology Fukuoka University, Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.02.026"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15454"},{"key":"e_1_2_11_4_1","volume-title":"Clinical Guideline for Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia (Revised 2020)","author":"The Japanese Urological Association","year":"2017"},{"key":"e_1_2_11_5_1","volume-title":"Clinical Guideline for Overactive Bladder Syndrome, 3rd ed","author":"The Japanese Continence Society, The Japanese Urological Association, eds","year":"2022"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192\u2010021\u201004736\u20108"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.019"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000738"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13596"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.022"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2021.01.021"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133940"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.02.042"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.06.020"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.091"},{"key":"e_1_2_11_17_1","volume-title":"Clinical Trials Act","author":"Ministry of Health, Labour, & Welfare","year":"2017"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003999"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102018\u2010021889"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894\u2010025\u201001742\u20106"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.05.093"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.04.001"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173096"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000381"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.149"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12535"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.70053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/luts.70053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.70053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:22:46Z","timestamp":1774585366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.70053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/luts.70053"],"URL":"https:\/\/doi.org\/10.1111\/luts.70053","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70053"}}